FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892504709> ?p ?o ?g. }

• W2892504709 endingPage "761" @default.
• W2892504709 startingPage "752" @default.
• W2892504709 abstract "We performed this study to observe the effects of different doses of ticagrelor and standard-dose clopidogrel on platelet reactivity and endothelial function in diabetic patients with stable coronary artery disease (CAD). Sixty type 2 diabetic patients were assigned to one-quarter standard-dose ticagrelor, half standard-dose ticagrelor, standard-dose ticagrelor and standard-dose clopidogrel groups. Light transmission aggregometry (LTA) and VerifyNow assay were used to measure platelet function. Endothelial function was assessed by measurement of flow-mediated vasodilation (FMD) and plasma von Willebrand factor (VWF) levels were detected. Enzyme-linked immunosorbent assay (ELISA) examined the Interleukin-8(IL-8) and IL-10. The results suggested that the one-quarter dose (34.0%± 14.7%), half-dose (26.9%± 11.6%) and standard-dose (17.3%± 10.3%) ticagrelor showed lower platelet aggregation rate than clopidogrel (52.8%± 18.3%; P ＜0.0001). PRU values in three ticagrelor groups were lower than that in clopidogrel group (102 (76-184)；75 (33-88)；38 (11-52) versus 194 (138-271) and；P ＜0.0001). FMD levels were higher in ticagrelor groups compared with baseline levels while lower in clopidogrel group after treatment. However, no significant differences were found in the percentage increase in the FMD between ticagrelor groups and clopidogrel group. The levels of VWF after treatment were lower than the baseline levels, but there was no statistically significant difference between ticagrelor group and clopidogrel group after treatment. The concentration of IL-8 and IL-10 were decreased in patients with half and standard-dose ticagrelor group. In conclusion, one-quarter standard-dose ticagrelor produced similar inhibitory effects on platelet aggregation as standard-dose clopidogrel in diabetic patients with stable CAD. The half standard-dose ticagrelor had a similar inhibitory effect on platelet inhibition as standard-dose ticagrelor, which was stronger than that of clopidogrel. Moreover, the half-dose ticagrelor had equal protection of endothelial function and inhibition of inflammatory factor as standard-dose ticagrelor." @default.
• W2892504709 created "2018-10-05" @default.
• W2892504709 creator A5003866201 @default.
• W2892504709 creator A5022992324 @default.
• W2892504709 creator A5024055037 @default.
• W2892504709 creator A5030760079 @default.
• W2892504709 creator A5030817762 @default.
• W2892504709 creator A5032565372 @default.
• W2892504709 creator A5038851564 @default.
• W2892504709 creator A5040722428 @default.
• W2892504709 creator A5057453861 @default.
• W2892504709 creator A5071499609 @default.
• W2892504709 date "2018-09-25" @default.
• W2892504709 modified "2023-10-17" @default.
• W2892504709 title "Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease" @default.
• W2892504709 cites W1473571458 @default.
• W2892504709 cites W1553834519 @default.
• W2892504709 cites W175512219 @default.
• W2892504709 cites W1976295549 @default.
• W2892504709 cites W1990018236 @default.
• W2892504709 cites W2012343501 @default.
• W2892504709 cites W2015641383 @default.
• W2892504709 cites W2040823835 @default.
• W2892504709 cites W2041872039 @default.
• W2892504709 cites W2062651794 @default.
• W2892504709 cites W2064776912 @default.
• W2892504709 cites W2064997581 @default.
• W2892504709 cites W2066618227 @default.
• W2892504709 cites W2085348618 @default.
• W2892504709 cites W2088253386 @default.
• W2892504709 cites W2093256230 @default.
• W2892504709 cites W2121897834 @default.
• W2892504709 cites W2140501627 @default.
• W2892504709 cites W2143852297 @default.
• W2892504709 cites W2153443504 @default.
• W2892504709 cites W2159382450 @default.
• W2892504709 cites W2161055506 @default.
• W2892504709 cites W2259865807 @default.
• W2892504709 cites W2271072014 @default.
• W2892504709 cites W2337601177 @default.
• W2892504709 cites W2342241145 @default.
• W2892504709 cites W2576157838 @default.
• W2892504709 cites W2601065898 @default.
• W2892504709 cites W2605624108 @default.
• W2892504709 cites W2609813387 @default.
• W2892504709 cites W2611883203 @default.
• W2892504709 cites W2747484920 @default.
• W2892504709 cites W3183915260 @default.
• W2892504709 cites W4294183732 @default.
• W2892504709 doi "https://doi.org/10.1080/09537104.2018.1513479" @default.
• W2892504709 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30252571" @default.
• W2892504709 hasPublicationYear "2018" @default.
• W2892504709 type Work @default.
• W2892504709 sameAs 2892504709 @default.
• W2892504709 citedByCount "11" @default.
• W2892504709 countsByYear W28925047092020 @default.
• W2892504709 countsByYear W28925047092021 @default.
• W2892504709 countsByYear W28925047092022 @default.
• W2892504709 crossrefType "journal-article" @default.
• W2892504709 hasAuthorship W2892504709A5003866201 @default.
• W2892504709 hasAuthorship W2892504709A5022992324 @default.
• W2892504709 hasAuthorship W2892504709A5024055037 @default.
• W2892504709 hasAuthorship W2892504709A5030760079 @default.
• W2892504709 hasAuthorship W2892504709A5030817762 @default.
• W2892504709 hasAuthorship W2892504709A5032565372 @default.
• W2892504709 hasAuthorship W2892504709A5038851564 @default.
• W2892504709 hasAuthorship W2892504709A5040722428 @default.
• W2892504709 hasAuthorship W2892504709A5057453861 @default.
• W2892504709 hasAuthorship W2892504709A5071499609 @default.
• W2892504709 hasConcept C126322002 @default.
• W2892504709 hasConcept C164705383 @default.
• W2892504709 hasConcept C2777628954 @default.
• W2892504709 hasConcept C2777849778 @default.
• W2892504709 hasConcept C2778213512 @default.
• W2892504709 hasConcept C2780890252 @default.
• W2892504709 hasConcept C71924100 @default.
• W2892504709 hasConcept C89560881 @default.
• W2892504709 hasConcept C98274493 @default.
• W2892504709 hasConceptScore W2892504709C126322002 @default.
• W2892504709 hasConceptScore W2892504709C164705383 @default.
• W2892504709 hasConceptScore W2892504709C2777628954 @default.
• W2892504709 hasConceptScore W2892504709C2777849778 @default.
• W2892504709 hasConceptScore W2892504709C2778213512 @default.
• W2892504709 hasConceptScore W2892504709C2780890252 @default.
• W2892504709 hasConceptScore W2892504709C71924100 @default.
• W2892504709 hasConceptScore W2892504709C89560881 @default.
• W2892504709 hasConceptScore W2892504709C98274493 @default.
• W2892504709 hasFunder F4320321001 @default.
• W2892504709 hasFunder F4320335777 @default.
• W2892504709 hasIssue "6" @default.
• W2892504709 hasLocation W28925047091 @default.
• W2892504709 hasLocation W28925047092 @default.
• W2892504709 hasOpenAccess W2892504709 @default.
• W2892504709 hasPrimaryLocation W28925047091 @default.
• W2892504709 hasRelatedWork W1686411234 @default.
• W2892504709 hasRelatedWork W1967626982 @default.
• W2892504709 hasRelatedWork W2130667353 @default.
• W2892504709 hasRelatedWork W2544930002 @default.

• next